WASHINGTON (MarketWatch) -- A senior biotech company executive and two others were charged with insider trading by the Securities and Exchange Commission. Michael Fefferman, senior director of information technology at Ardea Biosciences, tipped his brother-in-law Chad Wiegand with information on two trials, a licensing agreement and the firm's eventual acquisition by AstraZeneca, the SEC said. Wiegand, a stockbroker, purchased Ardea stock in various accounts, and tipped his fellow broker Akis Eracleous, the SEC said. Fefferman, Wiegand, and Eracleous have agreed to settlements that are subject to court approval, the SEC said, and Wiegand and Eracleous have agreed to be barred from the industry and have also been criminally charged. Financial penalties haven't been determined. One of Eracleous customers agreed to return the $219,175 in profits and interest, the SEC added.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information.
All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.
Intraday data delayed at least 15 minutes or per exchange requirements.